Does parenteral Omega-3 fatty acid administration increase the risk of atrial fibrillation? An analysis of the current evidence

Hartl et al., 2025 | Clin Nutr | Systematic Review

Citation

Hartl Wolfgang H, Meybohm Patrick, ... von Loeffelholz Christian. Does parenteral Omega-3 fatty acid administration increase the risk of atrial fibrillation? An analysis of the current evidence. Clin Nutr. 2025-Dec;55:223-230. doi:10.1016/j.clnu.2025.11.013

Abstract

BACKGROUND & AIMS: In 2023, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) issued new safety information on oral fish oil (FO) pharmacotherapy. This information indicated a dose-related increased risk of atrial fibrillation (AF) with FO in patients with established cardiovascular disease (CVD). The aim of this study is to analyse the existing evidence on this risk and establish whether it can be extrapolated to FO-enriched intravenous lipid emulsions (FO-ILEs) or to other patient groups, such as critically ill patients with organ dysfunction. METHODS: We searched for large (>50,000 participants) systematic reviews analysing the effect of long-term (>1 year) oral FO pharmacotherapy on the incidence of AF in non-critically ill patients with CVD. Reviews also had to include at least one large randomised study (>1,000 participants) on this topic. We examined these reviews with regard to specific limitations. We also estimated on a theoretical basis the extent to which short-term use of FO-ILEs in critically ill patients might alter plasmatic EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid) concentrations or myocardial EPA/DHA content, and investigated how these changes might affect the cardiac conduction system. We identified six meta-analyses, which consistently showed an increased risk of AF (primary, secondary, exploratory or safety outcome). In these analyses, however, significant bias may arise from including studies that ignored informative censoring or competing risks, or that used highly variable methods to search for AF. The results of these meta-analyses also conflicted with those of controlled trials in which AF was the primary endpoint, investigating the effect of long-term oral FO pharmacotherapy on the frequency of AF recurrence in patients with paroxysmal or persistent AF. Based on our theoretical considerations, it is unlikely that short-term (<4 weeks) use of FO-ILEs would increase EPA/DHA plasma concentrations or myocardial contents to levels that could induce AF in critically ill patients. RESULTS AND CONCLUSIONS: Short-term administration of FO-ILEs at the currently recommended dose (0.1-0.2 g/kg, corresponding to an average daily EPA/DHA intake of 4-6 g) can be considered safe from a critical care perspective in the setting of AF, especially when the duration of total parenteral nutrition is limited (<4 weeks).

Key Findings

Short-term administration of FO-ILEs at the currently recommended dose (0.1-0.2 g/kg, corresponding to an average daily EPA/DHA intake of 4-6 g) can be considered safe from a critical care perspective in the setting of AF, especially when the duration of total parenteral nutrition is limited (<4 weeks).

Outcomes Measured

• Requires manual extraction

Population

MeSH Terms

• Humans
• Atrial Fibrillation
• Fatty Acids, Omega-3
• Fish Oils
• Critical Illness
• Fat Emulsions, Intravenous
• Eicosapentaenoic Acid
• Risk Assessment

Evidence Classification

• Level: Systematic Review
• Publication Types: Journal Article, Systematic Review
• Vertical: omega-3

Provenance

• PMID: 41314109
• DOI: 10.1016/j.clnu.2025.11.013
• PMCID: Not in PMC
• Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09